GEN

GENOMED Active Actively listed

NEWCONNECT PL Biotechnologia

Latest report: Q1 2026, Published: May 14, 2026 Rating: 6.2/10

Neutral

Genomed to lider rynku badań NIPT w Polsce (jedyne laboratorium wykonujące ten test), z rosnącą sprzedażą usług sekwencjonowania NGS oraz oprogramowania BroVar.

Previous Previous ratings

FY/25

Analysis → Read analysis →

Market cap

—

no data

Announcements

/ 30 days

Reports

on file

Most important announcements in the last 30 days

Raport kwartalny za II kwartał Aug 13 2026

Finance

BETA

2 reports

The financial chart and controls are available after signing in.

Report analyses

2 of 2

Quarterly report Q1 2026

Genomed to lider rynku badań NIPT w Polsce (jedyne laboratorium wykonujące ten test), z rosnącą sprzedażą usług sekwencjonowania NGS oraz oprogramowania BroVar.

Neutral No guidance change Rating: 6.2/10

Report published: May 14 Analyzed: Jul 20

Annual report FY 2025

Lider polskiego rynku sekwencjonowania DNA (NGS) i diagnostyki genetycznej na NewConnect z rekordowym rokiem: przychody +26,6% r/r, zysk netto +207,6% r/r.

Positive No guidance change Rating: 7.5/10

Report published: May 26 Analyzed: Jul 13

Contracts

BETA

We haven't found any contracts in this company's filings

We only detect contracts from ESPI/EBI current filings and periodic reports, checked automatically every few minutes. The company may not have reported them in a detectable way, or our parser hasn't covered them yet.

Report a missing contract

Shareholders

6 holders

As of August 16, 2026 · ≥5% shareholder roster

Shareholders ≥5%: 85.93% Free float: 14.07%

Vote control

28.32%

Largest shareholder — Diagnostyka Spółka Akcyjna

Diagnostyka Spółka Akcyjna 41.17%

543,963

Marek Zagulski 20.07%

265,228

Anna Boguszewska-Chachulska 9.18%

121,236

Iwona Wach 5.6%

74,000

Andrzej Migdalski 4.96%

65,498

Andrzej Pałucha 4.95%

65,420

Free float 14.07%

—

Shareholder	% of capital	% of votes	Shares
Diagnostyka Spółka Akcyjna	41.17%	28.32%	543,963
Marek Zagulski	20.07%	27.45%	265,228
Anna Boguszewska-Chachulska	9.18%	12.01%	121,236
Iwona Wach	5.6%	7.71%	74,000
Andrzej Migdalski	4.96%	6.74%	65,498
Andrzej Pałucha	4.95%	6.81%	65,420
Free float	14.07%	10.96%	—

Free float

14.07%

Vote control

28.32%

Largest shareholder — Diagnostyka Spółka Akcyjna

Company data & listing Expand

Website: http://www.genomed.pl
Email: zarzad@genomed.pl
Sector: Biotechnologia
Industry: Biotechnologia
Exchange: NEWCONNECT
Country: PL
Reporting currency: PLN
FY end: 12-31
Standard: PL GAAP
ISIN: PLGNOMD00024
CEO: Anna Boguszewska-Chachulska
Address: UL. PONCZOWA 12 02-971 WARSZAWA
Phone: (22) 644 60 19
Listed since: May 17, 2026
Market cap: —
Status: Active